[1]
DeOliveira ML,Cunningham SC,Cameron JL,Kamangar F,Winter JM,Lillemoe KD,Choti MA,Yeo CJ,Schulick RD, Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of surgery. 2007 May;
[PubMed PMID: 17457168]
[2]
Bergquist A,Ekbom A,Olsson R,Kornfeldt D,Lööf L,Danielsson A,Hultcrantz R,Lindgren S,Prytz H,Sandberg-Gertzén H,Almer S,Granath F,Broomé U, Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. Journal of hepatology. 2002 Mar;
[PubMed PMID: 11867174]
[3]
Khan SA,Tavolari S,Brandi G, Cholangiocarcinoma: Epidemiology and risk factors. Liver international : official journal of the International Association for the Study of the Liver. 2019 Mar 9;
[PubMed PMID: 30851228]
[5]
Massarweh NN,El-Serag HB, Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer control : journal of the Moffitt Cancer Center. 2017 Jul-Sep
[PubMed PMID: 28975830]
[6]
Rahib L,Smith BD,Aizenberg R,Rosenzweig AB,Fleshman JM,Matrisian LM, Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014 Jun 1
[PubMed PMID: 24840647]
[7]
Hezel AF,Deshpande V,Zhu AX, Genetics of biliary tract cancers and emerging targeted therapies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Jul 20;
[PubMed PMID: 20547994]
[8]
Uson Junior PLS,Borad MJ, Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. Expert opinion on investigational drugs. 2022 Jan 7
[PubMed PMID: 34904492]
Level 3 (low-level) evidence
[9]
Yamada T,Nakanishi Y,Hayashi H,Tanishima S,Mori R,Fujii K,Okamura K,Tsuchikawa T,Nakamura T,Noji T,Asano T,Matsui A,Tanaka K,Watanabe Y,Kurashima Y,Ebihara Y,Murakami S,Shichinohe T,Mitsuhashi T,Hirano S, Targeted amplicon sequencing for primary tumors and matched lymph node metastases in patients with extrahepatic cholangiocarcinoma. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2021 Nov 25;
[PubMed PMID: 34903468]
[10]
Ahmad S,Badr B,Khan A,Rehman R,Ghias K,Muhammad JS,Khan MR, The Role of K-Ras and P53 in Biliary Tract Carcinoma. JPMA. The Journal of the Pakistan Medical Association. 2021 Oct;
[PubMed PMID: 34974575]
[11]
Nakeeb A,Pitt HA,Sohn TA,Coleman J,Abrams RA,Piantadosi S,Hruban RH,Lillemoe KD,Yeo CJ,Cameron JL, Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Annals of surgery. 1996 Oct;
[PubMed PMID: 8857851]
[12]
Akiba J,Nakashima O,Hattori S,Tanikawa K,Takenaka M,Nakayama M,Kondo R,Nomura Y,Koura K,Ueda K,Sanada S,Naito Y,Yamaguchi R,Yano H, Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. The American journal of surgical pathology. 2013 Apr;
[PubMed PMID: 23388123]
[13]
Blechacz B,Komuta M,Roskams T,Gores GJ, Clinical diagnosis and staging of cholangiocarcinoma. Nature reviews. Gastroenterology
[PubMed PMID: 21808282]
[14]
Carson SW,Craven KE,Nauen D,Montemayor K,Yarchoan M,Burns WR,Merlo CA,West NE, Rapidly progressive metastatic cholangiocarcinoma in a postpartum patient with cystic fibrosis: a case report. BMC pulmonary medicine. 2020 Nov 16
[PubMed PMID: 33198722]
Level 3 (low-level) evidence
[16]
Pelsang RE,Johlin FC, A percutaneous biopsy technique for patients with suspected biliary or pancreatic cancer without a radiographic mass. Abdominal imaging. 1997 May-Jun;
[PubMed PMID: 9107656]
[17]
Bismuth H,Nakache R,Diamond T, Management strategies in resection for hilar cholangiocarcinoma. Annals of surgery. 1992 Jan;
[PubMed PMID: 1309988]
[18]
Xin Y,Liu Q,Zhang J,Lu J,Song X,Zhan H,Chen X,Cao Z,Li Y,Huang Z, Hilar cholangiocarcinoma: Value of high-resolution enhanced magnetic resonance imaging for preoperative evaluation. Journal of cancer research and therapeutics. 2020;
[PubMed PMID: 33565510]
[19]
Bârcu A,Kraft A,Verdea C,Croitoru A,Lupescu I,Tomescu D,Popescu I,Botea F, En-Bloc Complete Segment 1 Resection and Left Hepatectomy for Klatskin Tumor. Chirurgia (Bucharest, Romania : 1990). 2021 Oct
[PubMed PMID: 34749860]
[20]
Fujiwara Y,Ioka T,Matsui H,Tokumitsu Y,Shindo Y,Matsukuma S,Nakajima M,Yamada K,Watanabe Y,Tomochika S,Yoshida S,Iida M,Suzuki N,Takeda S,Nagano H, [A Case of Intrahepatic Cholangiocarcinoma in the Elderly Patient with Curative Resection after Neoadjuvant Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy. 2021 Dec
[PubMed PMID: 35045501]
Level 3 (low-level) evidence
[21]
Casadio M,Cardinale V,Klümpen HJ,Morement H,Lacasta A,Koerkamp BG,Banales J,Alvaro D,Valle JW,Lamarca A, Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). ESMO open. 2022 Jan 27;
[PubMed PMID: 35093741]
[22]
Kihara Y,Takeda Y,Ohmura Y,Katsura Y,Shinke G,Yoshimura M,Haruna K,Kusafuka H,Sakaue M,Katsuyama S,Kawai K,Hiraki M,Masuzawa T,Hata T,Murata K, [Laparoscopic Liver Resection for Cholangiolocellular Carcinoma-A Single Institutional Experience]. Gan to kagaku ryoho. Cancer & chemotherapy. 2021 Dec
[PubMed PMID: 35045480]
[23]
Tee MC,Brahmbhatt RD,Franko J, Robotic Resection of Type I Hilar Cholangiocarcinoma with Intrapancreatic Bile Duct Dissection. Annals of surgical oncology. 2022 Feb;
[PubMed PMID: 34613533]
[24]
Seeger N,Grochola LF,Breitenstein S, [Gallbladder carcinoma and extrahepatic cholangiocarcinoma]. Therapeutische Umschau. Revue therapeutique. 2021
[PubMed PMID: 34844437]
[25]
Zeng N,Tao H,Fang C,Fan Y,Xiang N,Yang J,Zhu W,Liu J,Guan T,Fang C,Xiang F, Individualized preoperative planning using three-dimensional modeling for Bismuth and Corlette type III hilar cholangiocarcinoma. World journal of surgical oncology. 2016 Feb 24;
[PubMed PMID: 26911245]
[26]
Govil S,Reddy MS,Rela M, Surgical resection techniques for locally advanced hilar cholangiocarcinoma. Langenbeck's archives of surgery. 2014 Aug;
[PubMed PMID: 24893723]
[27]
Lu BC,Ren PT, Treatment of hilar cholangiocarcinoma of Bismuth-Corlette type III with hepaticojejunostomy. Contemporary oncology (Poznan, Poland). 2013;
[PubMed PMID: 24596518]
[28]
Goislard de Monsabert C,Touchefeu Y,Guiu B,Campillo-Gimenez B,Farges O,Tougeron D,Baumgaertner I,Ayav A,Beuzit L,Pracht M,Lièvre A,Le Sourd S,Boudjema K,Rolland Y,Garin E,Boucher E,Edeline J, Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas. Current oncology (Toronto, Ont.). 2021 Nov 8
[PubMed PMID: 34898592]
Level 2 (mid-level) evidence
[29]
Shroff RT,Kennedy EB,Bachini M,Bekaii-Saab T,Crane C,Edeline J,El-Khoueiry A,Feng M,Katz MHG,Primrose J,Soares HP,Valle J,Maithel SK, Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Mar 11;
[PubMed PMID: 30856044]
Level 1 (high-level) evidence
[30]
Bisello S,Renzulli M,Buwenge M,Calculli L,Sallustio G,Macchia G,Deodato F,Mattiucci G,Cammelli S,Arcelli A,Giaccherini L,Cellini F,Brandi G,Guerri S,Cilla S,Golfieri R,Fuccio L,Morganti AG,Guido A, An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer. Oncology letters. 2019 Feb;
[PubMed PMID: 30675238]
Level 3 (low-level) evidence
[31]
Hack SP,Zhu AX, Atezolizumab: an investigational agent for the treatment of biliary tract cancer. Expert opinion on investigational drugs. 2021 Oct;
[PubMed PMID: 34459336]
Level 3 (low-level) evidence
[32]
Hack SP,Verret W,Mulla S,Liu B,Wang Y,Macarulla T,Ren Z,El-Khoueiry AB,Zhu AX, IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Therapeutic advances in medical oncology. 2021
[PubMed PMID: 34377158]
Level 3 (low-level) evidence
[33]
Xu J,Bai Y,Sun H,Bai C,Jia R,Li Y,Zhang W,Liu L,Huang C,Guan M,Zhou J,Su W, A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer. 2021 Nov 1;
[PubMed PMID: 34355801]
[34]
Speer AG,Cotton PB,Russell RC,Mason RR,Hatfield AR,Leung JW,MacRae KD,Houghton J,Lennon CA, Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet (London, England). 1987 Jul 11;
[PubMed PMID: 2439854]
Level 1 (high-level) evidence
[35]
Wong SS,Yuen BT,Lee RK,Tsai CS,Cheung YS,Lee KF,Yu SCH, Percutaneous Portal Vein Embolization Using a Simplified Sheathless 18-Gauge Trocar Needle Approach: Review of Efficacy and Safety. Journal of vascular and interventional radiology : JVIR. 2019 Mar;
[PubMed PMID: 30819490]
[36]
Akinwande O,Shah V,Mills A,Noda C,Weiner E,Foltz G,Saad N, Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity. Hepatic oncology. 2017 Jul;
[PubMed PMID: 30191056]
Level 2 (mid-level) evidence